Barclays analyst Matt Miksic raised the firm’s price target on NuVasive to $58 from $56 and keeps an Overweight rating on the shares. The company delivered solid Q2 sales results and upside to earnings, but sales fell just shy of consensus, the analyst tells investors in a research note. While investors may question whether the business is losing momentum, NuVasive’s operating performance was solid, says the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUVA:
- NuVasive still expects 2023 net sales growth 6%-8%, revenue consensus $1.29B
- NuVasive reports Q2 non-GAAP EPS 56c, consensus 55c
- NuVasive Announces Second Quarter 2023 Financial Results
- NuVasive price target raised to $51 from $48 at Truist
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue